内科理论与实践 ›› 2022, Vol. 17 ›› Issue (06): 425-427.doi: 10.16138/j.1673-6087.2022.06.001
• 专家论坛 • 下一篇
侯健
收稿日期:
2021-11-22
出版日期:
2022-12-30
发布日期:
2023-02-27
HOU Jian
Received:
2021-11-22
Online:
2022-12-30
Published:
2023-02-27
中图分类号:
侯健. 治愈多发性骨髓瘤,敢问路在何方[J]. 内科理论与实践, 2022, 17(06): 425-427.
HOU Jian. The prospect of cure on multiple myeloma[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 425-427.
[1] |
Anderson KC. Progress and paradigms in multiple myeloma[J]. Clin Cancer Res, 2016, 22(22): 5419-5427.
doi: 10.1158/1078-0432.CCR-16-0625 pmid: 28151709 |
[2] |
Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma[J]. Mayo Clin Proc, 2004, 79(7): 867-874.
doi: 10.4065/79.7.867 pmid: 15244382 |
[3] |
Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J]. J Clin Oncol, 2014, 32(6): 587-600.
doi: 10.1200/JCO.2013.48.7934 pmid: 24419113 |
[4] |
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15(12): e538-e548.
doi: 10.1016/S1470-2045(14)70442-5 URL |
[5] |
Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma[J]. Nat Rev Dis Primers, 2017, 3: 17046.
doi: 10.1038/nrdp.2017.46 pmid: 28726797 |
[6] |
Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage Ⅰ multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study[J]. Br J Cancer, 2000, 82(7): 1254-1260.
doi: 10.1054/bjoc.1999.1087 URL |
[7] |
D’Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study[J]. Leuk Lymphoma, 2011, 52(5): 771-775.
doi: 10.3109/10428194.2011.553000 URL |
[8] |
Witzig TE, Laumann KM, Lacy MQ, et al. A phase Ⅲ randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma[J]. Leukemia, 2013, 27(1): 220-225.
doi: 10.1038/leu.2012.236 pmid: 22902362 |
[9] |
Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma[J]. J Clin Oncol, 2020, 38(11): 1126-1137.
doi: 10.1200/JCO.19.01740 pmid: 31652094 |
[10] |
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2020, 95(5): 548-567.
doi: 10.1002/ajh.25791 pmid: 32212178 |
[11] |
Suzuki K, Nishiwaki K, Yano S. Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity[J]. Cancers (Basel), 2021, 13(19): 4867.
doi: 10.3390/cancers13194867 URL |
[12] |
Caers J. The road to a cure: emerging treatments for multiple myeloma[J]. Cancers (Basel), 2020, 12(12): 3593.
doi: 10.3390/cancers12123593 URL |
[13] |
Agarwal JR, Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis[J]. Anticancer Agents Med Chem, 2010, 10(2): 116-120.
doi: 10.2174/187152010790909344 URL |
[14] |
Issa ME, Cretton S, Cuendet M. Targeting multiple myeloma cancer stem cells with natural products[J]. Planta Med, 2017, 83(9): 752-760.
doi: 10.1055/s-0043-109558 URL |
[15] |
Shi F, Li M, Wang J, et al. Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles[J]. Stem Cell Res Ther, 2018, 9(1): 144.
doi: 10.1186/s13287-018-0885-2 pmid: 29784015 |
[16] |
Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma[J]. Blood Adv, 2020, 4(23): 5988-5999.
doi: 10.1182/bloodadvances.2020002827 pmid: 33284948 |
[17] |
Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma[J]. Blood, 2018, 132(23): 2456-2464.
doi: 10.1182/blood-2018-06-858613 pmid: 30249784 |
[18] |
Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma[J]. J Clin Oncol, 2013, 31(20): 2540-2547.
doi: 10.1200/JCO.2012.46.2119 pmid: 23733781 |
[19] |
Avet-Loiseau H, Ludwig H, Landgren O, et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(1): e30-e37.
doi: 10.1016/j.clml.2019.09.622 pmid: 31780415 |
[20] |
Ghiaur G, Gerber J, Jones RJ. Concise review: cancer stem cells and minimal residual disease[J]. Stem Cells, 2012, 30(1): 89-93.
doi: 10.1002/stem.769 pmid: 22045578 |
[21] |
Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma[J]. Nat Rev Cancer, 2017, 17(9): 543-556.
doi: 10.1038/nrc.2017.63 pmid: 28835722 |
[22] |
Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma[J]. Int J Clin Oncol, 2015, 20(3): 413-422.
doi: 10.1007/s10147-015-0837-0 pmid: 25953678 |
[23] |
Miething CC. Clonal evolution in myeloma[J]. Haematologica, 2019, 104(7): 1292-1293.
doi: 10.3324/haematol.2019.220152 URL |
[24] |
Jones JR, Weinhold N, Ashby C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients[J]. Haematologica, 2019, 104(7): 1440-1450.
doi: 10.3324/haematol.2018.202200 pmid: 30733268 |
[25] |
Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma[J]. Immunol Rev, 2015, 263(1): 160-172.
doi: 10.1111/imr.12233 pmid: 25510276 |
[26] |
Lomas OC, Tahri S, Ghobrial IM. The microenvironment in myeloma[J]. Curr Opin Oncol, 2020, 32(2): 170-175.
doi: 10.1097/CCO.0000000000000615 pmid: 31895122 |
[27] |
Mahaweni NM, Ehlers FAI, Bos GMJ, et al. Tuning natural killer cell anti-multiple myeloma reactivity by targeting inhibitory signaling via KIR and NKG2A[J]. Front Immunol, 2018, 9: 2848.
doi: 10.3389/fimmu.2018.02848 pmid: 30564241 |
[28] |
Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma[J]. Blood, 2020, 136(24): 2731-2740.
doi: 10.1182/blood.2020006540 pmid: 32645135 |
[29] |
Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma[J]. Cancer Treat Rev, 2021, 100: 102284.
doi: 10.1016/j.ctrv.2021.102284 URL |
[30] |
Choudhry P, Galligan D, Wiita AP. Seeking convergence and cure with new myeloma therapies[J]. Trends Cancer, 2018, 4(8): 567-582.
doi: S2405-8033(18)30127-4 pmid: 30064664 |
[31] |
D’Agostino M, Bertamini L, Oliva S, et al. Pursuing a curative approach in multiple myeloma[J]. Cancers (Basel), 2019, 11(12): 2015.
doi: 10.3390/cancers11122015 URL |
[32] | Munshi NC. Introduction by the guest editor[J]. Cancer J, 2019, 25(1): 1. |
[33] |
Katodritou E, Papadaki S, Konstantinidou P, et al. Is it possible to cure myeloma without allogeneic transplantation?[J]. Transfus Apher Sci, 2016, 54(1): 63-70.
doi: 10.1016/j.transci.2016.01.015 pmid: 26850930 |
[1] | 谢富安, 任彦韬, 李文岗. 腹膜后脂肪肉瘤研究现状和困境[J]. 外科理论与实践, 2022, 27(06): 521-525. |
[2] | 马雪菲, 王学锋, 王侃侃. 浆细胞瘤变异体易位1和MYC基因在泛癌中的表达及生存期预测价值分析[J]. 诊断学理论与实践, 2022, 21(04): 490-496. |
[3] | 徐娜娜, 吴涛, 毛东锋, 薛锋, 刘文慧, 王宗慧, 白海. 肾脏原发髓外浆细胞瘤1例[J]. 内科理论与实践, 2022, 17(03): 253-255. |
[4] | 杨哲宇, 陆骋豪(综述), 蔡伟(审校). 浆细胞样树突状细胞与肿瘤免疫研究的新进展[J]. 外科理论与实践, 2021, 26(6): 568-572. |
[5] | 陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528. |
[6] | 寇明坤, 徐娜娜, 石静云, 吴涛. 达妥木单抗在多发性骨髓瘤一线治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(06): 588-591. |
[7] | 赵建治, 糜坚青. 多发性骨髓瘤相关生物标志物的研究进展[J]. 诊断学理论与实践, 2021, 20(05): 507-511. |
[8] | 范春丽, 吴涛, 薛锋, 胡文雪, 王存邦, 白海. MUM1/IRF4阳性弥漫大B细胞淋巴瘤一例治疗报告并文献复习[J]. 诊断学理论与实践, 2021, 20(04): 399-400. |
[9] | 彭真萍, 项喜喜, 张苏江, 李佳明. 以类白血病反应为首发表现的慢性中性粒细胞白血病二例并文献复习[J]. 诊断学理论与实践, 2020, 19(02): 122-128. |
[10] | 鲍婉婷,郭善禹,田宝星,曹丽辰,朱晨芳,冯少青,黄晓莺. 常规外科联合中医辨论治及整形修复技术治疗复杂浆细胞性乳腺炎[J]. 组织工程与重建外科杂志, 2019, 15(4): 256-259. |
[11] | 何柳,廖明娟,蔡彦韬,朱晨芳. 浆乳方联合乳房成形术及持续负压灌洗技术治疗难治性浆细胞性乳腺炎[J]. 组织工程与重建外科杂志, 2019, 15(3): 171-175. |
[12] | 陆弘逾, 曹亚峰, 顾俊, 王静, 陈梅, 宋陆茜. 神经电生理检查对多发性骨髓瘤患者硼替佐米治疗相关周围神经病的预测及诊断意义[J]. 诊断学理论与实践, 2019, 18(06): 640-644. |
[13] | 金诗炜, 糜坚青,. 嵌合抗原受体修饰的T细胞治疗多发性骨髓瘤的研究进展[J]. 内科理论与实践, 2019, 14(03): 196-201. |
[14] | 汪萍, 沈立松, 张冬青. 多发性骨髓瘤及相关疾病的实验室诊断认识[J]. 诊断学理论与实践, 2017, 16(05): 477-483. |
[15] | 李晓帆, 王少元. 多发性骨髓瘤微小残留病检测及其临床应用[J]. 诊断学理论与实践, 2017, 16(05): 472-476. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||